Results 271 to 280 of about 788,163 (356)

The Disquiet of Quiet Quitting: Definitional Clarity, Theoretical Pathways, and Future Research

open access: yesHuman Resource Management, EarlyView.
ABSTRACT Quiet quitting (QQ) has emerged as a prominent topic in both popular press and academic research, reflecting shifts in employees' engagement, effort allocation, and responses to contemporary work pressures. This review synthesizes findings from 11 papers published in a recent Special Issue on The Disquiet of Quiet Quitting.
Solon Magrizos   +5 more
wiley   +1 more source

Real‐world progression‐free survival and overall survival in patients with HR+/HER2− advanced breast cancer treated in first‐line with ribociclib, endocrine monotherapy or chemotherapy: Results from the observational RIBANNA study

open access: yesInternational Journal of Cancer, EarlyView.
What's New? The CDK4/6 inhibitor ribociclib in combination with an endocrine‐based therapy has demonstrated significant progression‐free and overall survival benefits in patients with advanced/metastatic HR+/HER2‐ breast cancer in the pivotal MONALEESA trials.
Peter A. Fasching   +20 more
wiley   +1 more source

ULK4 and CDKN2A polymorphisms influence the risk of developing monoclonal gammopathy of undetermined significance

open access: yesInternational Journal of Cancer, EarlyView.
What's New? Monoclonal gammopathy of undetermined significance (MGUS) is an asymptomatic precursor to multiple myeloma, sharing substantial genetic features with overt malignancy. Given evidence implicating autophagy in myeloma risk, this study examined whether genetic variations in autophagy‐related genes influence MGUS susceptibility.
José Manuel Sánchez‐Maldonado   +54 more
wiley   +1 more source

Availability of Cancer Screening Across HIV Treatment Sites in the IeDEA Consortium

open access: yesInternational Journal of Cancer, EarlyView.
In recent years, incorporating comprehensive cancer screening strategies into routine HIV care has gained growing attention. This survey of 220 sites providing HIV care across 41 countries shows that cervical cancer screening has increased in availability over time.
Rachael A. Pellegrino   +32 more
wiley   +1 more source

Cost‐effectiveness of a randomized controlled trial comparing low‐dose aspirin to placebo for the prevention of recurrent preterm birth

open access: yesInternational Journal of Gynecology &Obstetrics, Volume 169, Issue 1, Page 399-407, April 2025.
Abstract To assess the cost‐effectiveness of low‐dose aspirin compared to placebo for the prevention of recurrent preterm birth from a healthcare perspective. This was a cost‐effectiveness analysis alongside a multicenter, randomized, double‐blinded, placebo‐controlled trial.
Anadeijda J. E. M. C. Landman   +24 more
wiley   +1 more source

Home - About - Disclaimer - Privacy